NCT06730750Active, not recruitingPhase 1/2
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- First submitted
- 9 Dec 2024
- Start date
- 12 Feb 2025
- Primary completion date
- 5 Sept 2026
- Lead sponsor
- Bristol-Myers Squibb
- NCT number
- NCT06730750
- EudraCT number
- 2024-518421-14
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 360
- From 12 Feb 2025 to the primary completion date, 5 Sept 2026
- 6 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received therapy targeting CEACAM5.
Other illness
- History of anaphylactic reactions to irinotecan and/or bevacizumab.
- Grade ≥3 ILD/pneumonitis.
Other
- Other protocol-defined Inclusion/Exclusion criteria apply.
Who the study is looking for
- Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1.
- CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:
- Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not contraindicated).
- NSCLC: Part 2A-NSCLC/GC, 2L+ NSCLC:
- Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease.
- Participants must have received and progressed on or after anti-PD-(L)1 therapy, if available.
- \- GC: Part 2A-NSCLC/GC, 2L+ GC: i) Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy).
- ECOG performance status of 0 or 1.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tasman Oncology Research Coordinator of this site? Confirm its status | Southport | Australia | Unknown status |
| - Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Hackensack | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.